Jupiter Topco LLC Purchases Shares of 3,954,691 Lexeo Therapeutics, Inc. $LXEO

Jupiter Topco LLC purchased a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the second quarter, Holdings Channel.com reports. The firm purchased 3,954,691 shares of the company’s stock, valued at approximately $18,409,000. Jupiter Topco LLC owned approximately 0.05% of Lexeo Therapeutics at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at $1,237,000. Dimensional Fund Advisors LP boosted its stake in Lexeo Therapeutics by 27.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company’s stock worth $6,332,000 after acquiring an additional 240,692 shares in the last quarter. Spruce Street Capital LP grew its holdings in Lexeo Therapeutics by 430.6% in the first quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock worth $5,330,000 after purchasing an additional 753,593 shares during the period. Orbimed Advisors LLC grew its holdings in Lexeo Therapeutics by 69.5% in the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock worth $20,678,000 after purchasing an additional 1,477,450 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in Lexeo Therapeutics by 57.8% in the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock valued at $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Richard Nolan Townsend sold 25,947 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares in the company, valued at $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider owned 82,194 shares of the company’s stock, valued at $363,297.48. This trade represents a 21.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 66,326 shares of company stock worth $299,817 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Lexeo Therapeutics Price Performance

NASDAQ:LXEO opened at $4.86 on Friday. Lexeo Therapeutics, Inc. has a one year low of $3.99 and a one year high of $10.99. The company has a market cap of $398.74 million, a PE ratio of -4.23 and a beta of 1.46. The firm has a 50-day moving average of $4.74 and a 200-day moving average of $5.46.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, equities research analysts expect that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. decreased their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Wall Street Zen downgraded Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.75.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.